Regulatory landscape and clinical implication of MBD3 in human malignant glioma

Yi Cui, Jian Li, Ling Weng, Sara E. Wirbisky, Jennifer L. Freeman, Jingping Liu, Qing Liu, Xianrui Yuan, Joseph Irudayaraj

Research output: Contribution to journalArticle

Abstract

In this article we inspect the roles and functions of the methyl-CpG-binding domain protein 3 (MBD3) in human malignant glioma, to assess its potential as an epigenetic biomarker for prognosis. The regulatory effects of MBD3 on glioma transcriptome were first profiled by high-throughput microarray. Our results indicate that MBD3 is involved in both transcriptional activation and repression. Furthermore, MBD3 fine-controls a spectrum of proteins critical for cellular metabolism and proliferation, thereby contributing to an exquisite anti-glioma network. Specifically, the expression of MHC class II molecules was found to positively correlate with MBD3, which provides new insight into the immune escape of gliomagenesis. In addition, MBD3 participates in constraining a number of oncogenic non-coding RNAs whose over-activation could drive cells into excessive growth and higher malignancy. Having followed up a pilot cohort, we noted that the survival of malignant glioma patients was proportional to the content of MBD3 and 5-hydroxymethylcytosine (5hmC) in their tumor cells. The progression-free survival (PFS) and overall survival (OS) were relatively poor for patients with lower amount of MBD3 and 5hmC in the tissue biopsies. Taken together, this work enriches our understanding of the mechanistic involvement of MBD3 in malignant glioma.

Original languageEnglish (US)
Pages (from-to)81698-81714
Number of pages17
JournalOncotarget
Volume7
Issue number49
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Glioma
Carrier Proteins
Untranslated RNA
Survival
human MBD3 protein
Methyl CpG Binding Domain
Transcriptome
Epigenomics
Transcriptional Activation
Disease-Free Survival
Neoplasms
Biomarkers
Cell Proliferation
Biopsy
Growth
Proteins

Keywords

  • DNA methylation
  • Epigenetics
  • Glioma
  • MBD3
  • Prognostic biomarker

ASJC Scopus subject areas

  • Oncology

Cite this

Cui, Y., Li, J., Weng, L., Wirbisky, S. E., Freeman, J. L., Liu, J., ... Irudayaraj, J. (2016). Regulatory landscape and clinical implication of MBD3 in human malignant glioma. Oncotarget, 7(49), 81698-81714. https://doi.org/10.18632/oncotarget.13173

Regulatory landscape and clinical implication of MBD3 in human malignant glioma. / Cui, Yi; Li, Jian; Weng, Ling; Wirbisky, Sara E.; Freeman, Jennifer L.; Liu, Jingping; Liu, Qing; Yuan, Xianrui; Irudayaraj, Joseph.

In: Oncotarget, Vol. 7, No. 49, 01.01.2016, p. 81698-81714.

Research output: Contribution to journalArticle

Cui, Y, Li, J, Weng, L, Wirbisky, SE, Freeman, JL, Liu, J, Liu, Q, Yuan, X & Irudayaraj, J 2016, 'Regulatory landscape and clinical implication of MBD3 in human malignant glioma', Oncotarget, vol. 7, no. 49, pp. 81698-81714. https://doi.org/10.18632/oncotarget.13173
Cui Y, Li J, Weng L, Wirbisky SE, Freeman JL, Liu J et al. Regulatory landscape and clinical implication of MBD3 in human malignant glioma. Oncotarget. 2016 Jan 1;7(49):81698-81714. https://doi.org/10.18632/oncotarget.13173
Cui, Yi ; Li, Jian ; Weng, Ling ; Wirbisky, Sara E. ; Freeman, Jennifer L. ; Liu, Jingping ; Liu, Qing ; Yuan, Xianrui ; Irudayaraj, Joseph. / Regulatory landscape and clinical implication of MBD3 in human malignant glioma. In: Oncotarget. 2016 ; Vol. 7, No. 49. pp. 81698-81714.
@article{5c26053b01da43afb5f33974c90d85ea,
title = "Regulatory landscape and clinical implication of MBD3 in human malignant glioma",
abstract = "In this article we inspect the roles and functions of the methyl-CpG-binding domain protein 3 (MBD3) in human malignant glioma, to assess its potential as an epigenetic biomarker for prognosis. The regulatory effects of MBD3 on glioma transcriptome were first profiled by high-throughput microarray. Our results indicate that MBD3 is involved in both transcriptional activation and repression. Furthermore, MBD3 fine-controls a spectrum of proteins critical for cellular metabolism and proliferation, thereby contributing to an exquisite anti-glioma network. Specifically, the expression of MHC class II molecules was found to positively correlate with MBD3, which provides new insight into the immune escape of gliomagenesis. In addition, MBD3 participates in constraining a number of oncogenic non-coding RNAs whose over-activation could drive cells into excessive growth and higher malignancy. Having followed up a pilot cohort, we noted that the survival of malignant glioma patients was proportional to the content of MBD3 and 5-hydroxymethylcytosine (5hmC) in their tumor cells. The progression-free survival (PFS) and overall survival (OS) were relatively poor for patients with lower amount of MBD3 and 5hmC in the tissue biopsies. Taken together, this work enriches our understanding of the mechanistic involvement of MBD3 in malignant glioma.",
keywords = "DNA methylation, Epigenetics, Glioma, MBD3, Prognostic biomarker",
author = "Yi Cui and Jian Li and Ling Weng and Wirbisky, {Sara E.} and Freeman, {Jennifer L.} and Jingping Liu and Qing Liu and Xianrui Yuan and Joseph Irudayaraj",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.13173",
language = "English (US)",
volume = "7",
pages = "81698--81714",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "49",

}

TY - JOUR

T1 - Regulatory landscape and clinical implication of MBD3 in human malignant glioma

AU - Cui, Yi

AU - Li, Jian

AU - Weng, Ling

AU - Wirbisky, Sara E.

AU - Freeman, Jennifer L.

AU - Liu, Jingping

AU - Liu, Qing

AU - Yuan, Xianrui

AU - Irudayaraj, Joseph

PY - 2016/1/1

Y1 - 2016/1/1

N2 - In this article we inspect the roles and functions of the methyl-CpG-binding domain protein 3 (MBD3) in human malignant glioma, to assess its potential as an epigenetic biomarker for prognosis. The regulatory effects of MBD3 on glioma transcriptome were first profiled by high-throughput microarray. Our results indicate that MBD3 is involved in both transcriptional activation and repression. Furthermore, MBD3 fine-controls a spectrum of proteins critical for cellular metabolism and proliferation, thereby contributing to an exquisite anti-glioma network. Specifically, the expression of MHC class II molecules was found to positively correlate with MBD3, which provides new insight into the immune escape of gliomagenesis. In addition, MBD3 participates in constraining a number of oncogenic non-coding RNAs whose over-activation could drive cells into excessive growth and higher malignancy. Having followed up a pilot cohort, we noted that the survival of malignant glioma patients was proportional to the content of MBD3 and 5-hydroxymethylcytosine (5hmC) in their tumor cells. The progression-free survival (PFS) and overall survival (OS) were relatively poor for patients with lower amount of MBD3 and 5hmC in the tissue biopsies. Taken together, this work enriches our understanding of the mechanistic involvement of MBD3 in malignant glioma.

AB - In this article we inspect the roles and functions of the methyl-CpG-binding domain protein 3 (MBD3) in human malignant glioma, to assess its potential as an epigenetic biomarker for prognosis. The regulatory effects of MBD3 on glioma transcriptome were first profiled by high-throughput microarray. Our results indicate that MBD3 is involved in both transcriptional activation and repression. Furthermore, MBD3 fine-controls a spectrum of proteins critical for cellular metabolism and proliferation, thereby contributing to an exquisite anti-glioma network. Specifically, the expression of MHC class II molecules was found to positively correlate with MBD3, which provides new insight into the immune escape of gliomagenesis. In addition, MBD3 participates in constraining a number of oncogenic non-coding RNAs whose over-activation could drive cells into excessive growth and higher malignancy. Having followed up a pilot cohort, we noted that the survival of malignant glioma patients was proportional to the content of MBD3 and 5-hydroxymethylcytosine (5hmC) in their tumor cells. The progression-free survival (PFS) and overall survival (OS) were relatively poor for patients with lower amount of MBD3 and 5hmC in the tissue biopsies. Taken together, this work enriches our understanding of the mechanistic involvement of MBD3 in malignant glioma.

KW - DNA methylation

KW - Epigenetics

KW - Glioma

KW - MBD3

KW - Prognostic biomarker

UR - http://www.scopus.com/inward/record.url?scp=85000916630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000916630&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13173

DO - 10.18632/oncotarget.13173

M3 - Article

C2 - 27835581

AN - SCOPUS:85000916630

VL - 7

SP - 81698

EP - 81714

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 49

ER -